EU/3/18/2133

About

On 11 January 2019, orphan designation (EU/3/18/2133) was granted by the European Commission to TLC Biopharmaceuticals B.V., the Netherlands, for vinorelbine tartrate for the treatment of soft tissue sarcoma.

Key facts

Active substance
Vinorelbine tartrate
Disease / condition
Treatment of soft tissue sarcoma
Date of first decision
11/01/2019
Outcome
Positive
EU designation number
EU/3/18/2133

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

 

Sponsor's contact details

J.h. Oortweg 19
2333 CH Leiden
Netherlands
Tel. + 31 (0) 71 33 22 340
E-mail: fl@euregulatoryconsultant.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating